chimeric mouse human anti cd20 antibody rituximab c2b8  (Biogen Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Biogen Inc chimeric mouse human anti cd20 antibody rituximab c2b8
    Characterization of purified <t>rituximab</t> minibody and scFv-Fc DM. A) Schematic presentations of the minibody and scFv-Fc DM. Both proteins assemble into covalent bound homodimers through cysteines in the hinge region. The two mutations (H310A and H435Q) present in the Fc region are indicated. V L = variable light. V H = variable heavy. C H = constant heavy. B) Coomassie stained SDS-PAGE of purified proteins under non-reducing (lanes 2) and reducing (lanes 3) conditions. Lane 1 = molecular marker. C) Size-exclusion chromatography analysis of purified minibody and scFv-Fc DM. D) Flow cytometric analysis of <t>CD20</t> binding by rituximab antibody fragments. Purified proteins were assayed for binding to 38C13-huCD20 cells. Bound protein was detected with phycoerythrin (PE) conjugated goat anti-human (Fc specific) antibodies. Rituximab was used as positive control and secondary antibody alone as negative control.
    Chimeric Mouse Human Anti Cd20 Antibody Rituximab C2b8, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/chimeric mouse human anti cd20 antibody rituximab c2b8/product/Biogen Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    chimeric mouse human anti cd20 antibody rituximab c2b8 - by Bioz Stars, 2021-07
    86/100 stars

    Images

    1) Product Images from "Recombinant anti-CD20 antibody fragments for microPET imaging of B-cell lymphoma"

    Article Title: Recombinant anti-CD20 antibody fragments for microPET imaging of B-cell lymphoma

    Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

    doi: 10.2967/jnumed.108.060426

    Characterization of purified rituximab minibody and scFv-Fc DM. A) Schematic presentations of the minibody and scFv-Fc DM. Both proteins assemble into covalent bound homodimers through cysteines in the hinge region. The two mutations (H310A and H435Q) present in the Fc region are indicated. V L = variable light. V H = variable heavy. C H = constant heavy. B) Coomassie stained SDS-PAGE of purified proteins under non-reducing (lanes 2) and reducing (lanes 3) conditions. Lane 1 = molecular marker. C) Size-exclusion chromatography analysis of purified minibody and scFv-Fc DM. D) Flow cytometric analysis of CD20 binding by rituximab antibody fragments. Purified proteins were assayed for binding to 38C13-huCD20 cells. Bound protein was detected with phycoerythrin (PE) conjugated goat anti-human (Fc specific) antibodies. Rituximab was used as positive control and secondary antibody alone as negative control.
    Figure Legend Snippet: Characterization of purified rituximab minibody and scFv-Fc DM. A) Schematic presentations of the minibody and scFv-Fc DM. Both proteins assemble into covalent bound homodimers through cysteines in the hinge region. The two mutations (H310A and H435Q) present in the Fc region are indicated. V L = variable light. V H = variable heavy. C H = constant heavy. B) Coomassie stained SDS-PAGE of purified proteins under non-reducing (lanes 2) and reducing (lanes 3) conditions. Lane 1 = molecular marker. C) Size-exclusion chromatography analysis of purified minibody and scFv-Fc DM. D) Flow cytometric analysis of CD20 binding by rituximab antibody fragments. Purified proteins were assayed for binding to 38C13-huCD20 cells. Bound protein was detected with phycoerythrin (PE) conjugated goat anti-human (Fc specific) antibodies. Rituximab was used as positive control and secondary antibody alone as negative control.

    Techniques Used: Purification, Staining, SDS Page, Marker, Size-exclusion Chromatography, Flow Cytometry, Binding Assay, Positive Control, Negative Control

    Related Articles

    other:

    Article Title: Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
    Article Snippet: In 1997,rituximab (MabThera®,Rituxan®; Roche/Genentech/Biogen IDEC),a chimeric,human-mouse,IgG1 anti-CD20 mAb,was the first mAb approved by United States Food and Drug Administration for the treatment of lymphoma.

    Generated:

    Article Title: ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies)
    Article Snippet: .. A total of five different scFv variants were generated from the variable domains of the chimeric (mouse/human) anti-CD20 antibody rituximab C2B8 (Rituxan® , Genentech/Biogen-IDEC, San Francisco, CA, USA). .. The variants were assessed for binding to CD20 and size was determined by size-exclusion chromatography.

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Biogen Inc chimeric mouse human anti cd20 antibody rituximab c2b8
    Characterization of purified <t>rituximab</t> minibody and scFv-Fc DM. A) Schematic presentations of the minibody and scFv-Fc DM. Both proteins assemble into covalent bound homodimers through cysteines in the hinge region. The two mutations (H310A and H435Q) present in the Fc region are indicated. V L = variable light. V H = variable heavy. C H = constant heavy. B) Coomassie stained SDS-PAGE of purified proteins under non-reducing (lanes 2) and reducing (lanes 3) conditions. Lane 1 = molecular marker. C) Size-exclusion chromatography analysis of purified minibody and scFv-Fc DM. D) Flow cytometric analysis of <t>CD20</t> binding by rituximab antibody fragments. Purified proteins were assayed for binding to 38C13-huCD20 cells. Bound protein was detected with phycoerythrin (PE) conjugated goat anti-human (Fc specific) antibodies. Rituximab was used as positive control and secondary antibody alone as negative control.
    Chimeric Mouse Human Anti Cd20 Antibody Rituximab C2b8, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/chimeric mouse human anti cd20 antibody rituximab c2b8/product/Biogen Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    chimeric mouse human anti cd20 antibody rituximab c2b8 - by Bioz Stars, 2021-07
    86/100 stars
      Buy from Supplier

    86
    Biogen Inc rituximab
    Antibody-mediated C1q binding on the surface of target cells. IM-9, U266, HL-60, or Ramos cells were incubated with 5 μg/mL of <t>rituximab,</t> the parental ch128.1, or the fusion protein ch128.1Av for 30 minutes at room temperature. Samples treated
    Rituximab, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rituximab/product/Biogen Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rituximab - by Bioz Stars, 2021-07
    86/100 stars
      Buy from Supplier

    Image Search Results


    Characterization of purified rituximab minibody and scFv-Fc DM. A) Schematic presentations of the minibody and scFv-Fc DM. Both proteins assemble into covalent bound homodimers through cysteines in the hinge region. The two mutations (H310A and H435Q) present in the Fc region are indicated. V L = variable light. V H = variable heavy. C H = constant heavy. B) Coomassie stained SDS-PAGE of purified proteins under non-reducing (lanes 2) and reducing (lanes 3) conditions. Lane 1 = molecular marker. C) Size-exclusion chromatography analysis of purified minibody and scFv-Fc DM. D) Flow cytometric analysis of CD20 binding by rituximab antibody fragments. Purified proteins were assayed for binding to 38C13-huCD20 cells. Bound protein was detected with phycoerythrin (PE) conjugated goat anti-human (Fc specific) antibodies. Rituximab was used as positive control and secondary antibody alone as negative control.

    Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

    Article Title: Recombinant anti-CD20 antibody fragments for microPET imaging of B-cell lymphoma

    doi: 10.2967/jnumed.108.060426

    Figure Lengend Snippet: Characterization of purified rituximab minibody and scFv-Fc DM. A) Schematic presentations of the minibody and scFv-Fc DM. Both proteins assemble into covalent bound homodimers through cysteines in the hinge region. The two mutations (H310A and H435Q) present in the Fc region are indicated. V L = variable light. V H = variable heavy. C H = constant heavy. B) Coomassie stained SDS-PAGE of purified proteins under non-reducing (lanes 2) and reducing (lanes 3) conditions. Lane 1 = molecular marker. C) Size-exclusion chromatography analysis of purified minibody and scFv-Fc DM. D) Flow cytometric analysis of CD20 binding by rituximab antibody fragments. Purified proteins were assayed for binding to 38C13-huCD20 cells. Bound protein was detected with phycoerythrin (PE) conjugated goat anti-human (Fc specific) antibodies. Rituximab was used as positive control and secondary antibody alone as negative control.

    Article Snippet: The chimeric (mouse/human) anti-CD20 antibody rituximab C2B8 (Rituxan® , Genentech/Biogen-IDEC, San Francisco, CA) has become a mainstay in the treatment of B cell NHL, achieving high response rates in low-grade B cell lymphomas , and improvements in survival in both low-grade and aggressive lymphomas when combined with chemotherapy ( , ).

    Techniques: Purification, Staining, SDS Page, Marker, Size-exclusion Chromatography, Flow Cytometry, Binding Assay, Positive Control, Negative Control

    Antibody-mediated C1q binding on the surface of target cells. IM-9, U266, HL-60, or Ramos cells were incubated with 5 μg/mL of rituximab, the parental ch128.1, or the fusion protein ch128.1Av for 30 minutes at room temperature. Samples treated

    Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

    Article Title: An Antibody-based Multifaceted Approach Targeting the Human Transferrin Receptor for the Treatment of B-cell Malignancies

    doi: 10.1097/CJI.0b013e318222ffc8

    Figure Lengend Snippet: Antibody-mediated C1q binding on the surface of target cells. IM-9, U266, HL-60, or Ramos cells were incubated with 5 μg/mL of rituximab, the parental ch128.1, or the fusion protein ch128.1Av for 30 minutes at room temperature. Samples treated

    Article Snippet: In addition, rituximab (mouse/human chimeric anti-CD20 IgG1) was purchased from Biogen IDEC, Inc. (Cambridge, MA).

    Techniques: Binding Assay, Incubation